ライフサイエンスコーパス: pentazocine

1 phorylation decreased in the presence of (+)-pentazocine.

2 fect was decreased by the application of (+)-pentazocine.

3 n the Ins2Akita/+ mice were treated with (+)-pentazocine.

4 stress, but decreased in the presence of (+)-pentazocine.

5 typic sigma-1 agonists (+)-SKF10,047 and (+)-pentazocine.

6 ocine > DTG (1, 3-di-o-tolylguanidine) > (-)-pentazocine.

7 e animals were randomized to four groups: a) pentazocine (0.3 mg/kg), a delta-opioid receptor agonist

8 Pentazocine, a sigma ligand was without effect per se, b

9 In vivo, a 2.5 mg/kg dose of (+)-pentazocine abolished (11)C-Me-NB1-specific binding, ind

10 t striatum to that of the sigma agonists (+)-pentazocine and BD737.

11 In contrast to pentazocine and most 6,7-benzomorphans, the (1R,5R,9R)-i

12 Both (+)-pentazocine and NPY inhibit potassium-stimulated [(3)H]d

13 The sigma receptor ligands pentazocine and SKF10047 modulated K+ channels, despite

14 In contrast, ondansetron, pentazocine, and dimenhydrinate may be useful for treati

15 ophysis the sigma receptor ligands SKF10047, pentazocine, and ditolylguanidine all reversibly inhibit

16 m Ins2Akita/+ diabetic mice treated with (+)-pentazocine, and the expression of ER stress genes and o

17 the prototypical sigma receptor agonist (+)-pentazocine, and the proposed endogenous sigma receptor

18 PYX-1 also reversed the (+)-pentazocine- and BD737-mediated inhibition of release.

19 p of chemically unrelated ligands, including pentazocine, apomorphine (a dopamine receptor agonist) a

20 hibited normal, low affinity, and no [3H](+)-pentazocine binding activity, respectively.

21 a significant decrease in specific (+)-[(3)H]pentazocine binding.

22 Pentazocine binds only to sigma1 receptors.

23 ed by dehydroepiandrosterone sulfate and (+)-pentazocine but not by (-)-pentazocine, the synthetic (-

24 Like pentazocine, butorphanol was equally efficacious at acti

25 Rimcazole failed to inhibit pentazocine c-fos induction.

26 sigma-1 receptor was identified by (+)-[(3)H]pentazocine competitive binding with nonradioactive [(12

27 The primary effect of dextromethorphan, (+)-pentazocine, (+)-cyclazocine, (+)-SKF10047, carbetapenta

28 eptor (Sigma1R), and the Sigma1R agonist (+)-pentazocine did not compete for high-affinity binding.

29 tent with its low potency at p38 activation, pentazocine did not produce conditioned place aversion i

30 two known Sig1R ligands, haloperidol and (+)-pentazocine, disrupted the Nav1.5/Sig1R interaction both

31 te drugs (fentanyl, morphine, buprenorphine, pentazocine) followed by 2 hours of 34 degrees C ischemi

32 e received intraperitoneal injections of (+)-pentazocine for 22 weeks beginning at diabetes onset.

33 reserved in the morphine, buprenorphine, and pentazocine groups when compared with cardioplegia alone

34 nyl)ethylamine) > 4-IPBS > haloperidol > (+)-pentazocine > DTG (1, 3-di-o-tolylguanidine) > (-)-penta

35 ts in which (-)-PTZ, the levo-isomer form of pentazocine, had no neuroprotective effect on excitotoxi

36 etic small molecules, including cocaine, (+)-pentazocine, haloperidol, and small endogenous molecules

37 oportion of multimeric sigma1Rs, whereas (+)-pentazocine increased monomeric sigma1Rs.

38 hexane-1-carboxylate hydrochloride), and (+)-pentazocine increases the expression of GluN2A and GluN2

39 h selective sigma(1)R agonists (PRE-084, (+)-pentazocine) lacked reinforcing effects in drug-naive ra

40 systems because the final sigma agonist (+)-pentazocine lowered opioid analgesia in all mice, includ

41 R1 binds BiP under stressful conditions; (+)-pentazocine may exert its effects by dissociating sigmaR

42 ls, and the effect of the sigmaR1 ligand (+)-pentazocine on pro- and anti-apoptotic and endoplasmic r

43 Preincubation with (+)-pentazocine or PRE-084 increased the Bmax values of [(3)

44 Pentazocine or saline placebo was injected into the righ

45 In contrast to (+)-pentazocine- or BD737-mediated inhibition of release, NP

46 uP734, haloperidol and DTG) that reverse (+)-pentazocine- or BD737-mediated inhibition, as well as a

47 rt that the prototypical sigma1R agonist (+)-pentazocine potentiated the dose response of cocaine sel

48 mg/kg), a delta-opioid receptor agonist; b) pentazocine pretreated with KATP channel blocker, gliben

49 cells were used for binding assays with [3H]-pentazocine (PTZ).

50 and demonstrated that the sigmaR1 ligand (+)-pentazocine ((+)-PTZ) could protect against cell death.

51 ration of the high-affinity Sig1R ligand (+)-pentazocine [(+)-PTZ] to rd10 mice over several weeks le

52 , both in a sigma-ligand (haloperidol or (+)-pentazocine)-sensitive manner.

53 s using the sigma-1-selective ligand [3H](+)-pentazocine showed a high-affinity binding (Kd = 5.80 nM

54 e sulfate and (+)-pentazocine but not by (-)-pentazocine, the synthetic (-)-enantiomer of PREGS or th

55 cardiac index, was significantly improved in pentazocine-treated animals.

56 In the (+)-pentazocine-treated group, retinas of Ins2(Akita/+) mice

57 architecture; IPL and INL thicknesses of (+)-pentazocine-treated Ins2(Akita/+) mouse retinas were wit

58 Retinas of (+)-pentazocine-treated mice maintained the radial organizat

59 s2(Akita/+) retinas, but were reduced in (+)-pentazocine-treated mice.

60 +/- 1.2 cells/100 mum retinal length in (+)-pentazocine-treated versus nontreated mutant mice.

61 Sustained (+)-pentazocine treatment in an in vivo model of retinal deg

62 the prototypic sigma 1 receptor agonist (+)-pentazocine was found not to be neuroprotective.

63 Pentazocine was significantly more potent at activating

64 of defibrillation, the beneficial effects of pentazocine were abolished by pretreatment with the KATP

65 ligands, 1,3-di(2-tolyl)guanidine (DTG) and pentazocine, were shown to induce c-fos in similar patte

66 reported that the opioid agonist-antagonist pentazocine, which acts predominantly at kappa-receptors

67 Combining the sigma-1 agonist (+)-pentazocine with rimcazole substantially reduces the acc